The DISCOVER‐2 trial has shown that guselkumab, an interleukin‐23p19 was shown to be safe and effective in biologic‐naïve psoriatic arthritis (PsA) patients in a one year study.
Dr Philip Robinson philipcrobinson
5 years 11 months ago
ACTIV-1 run by the @NIH will test rheum drugs infliximab and abatacept in COVID-19. This is great news. https://t.co/IITzGTuxEC
Peter Nash drpnash
5 years 11 months ago
Incidence & Risk VTE Among Pts RA Enrolled in Upadacitinib Trial Program https://t.co/zCuWHZXV4h #VTE #Upadacitinib balanced VTE across trial programme in the expected 0.5-0.8/100 pt yrs range - past VTE & BMI risk factors, no mention COX2s - is VTE Jak2 effect or class effect?
JAMA Internal Medicine has published a review showing that most currently approved therapies for fibromyalgia (FM) do not have high-quality evidence to support their use; with some reducing pain or improving quality of life (QOL) in the short term, but overall effect size is not impressive.
Dr. John Cush RheumNow
5 years 11 months ago
New research shows potential utility of plasma specialized pro-resolving mediator (SPM; like RvD4, 10S, 17S-diHDPA, 15R-LXA4 and MaR1n-3 DPA) concentrations as biomarkers to predict DMARD responsiveness in #RA. https://t.co/WQb57EON10
Vedolizumab (Entyvio) was superior to infliximab (Remicade) for treating immune-mediated diarrhea and colitis (IMDC), a researcher reported.
In a retrospective study of patients with cancer, treatment with vedolizumab led to a 13% IMDC recurrence rate versus 28% with infliximab, according to Yinghong Wang, MD, PhD, of the MD Anderson Cancer Center in Houston.
A full read review of immune-mediated necrotizing myopathy is portrayed as a distinct subtype of inflammatory myopathies first described in 2004.
Dr. John Cush RheumNow
5 years 11 months ago
Review of 127 pts w/ diagnostic criteria for palindromic rheumatism - Most affected JTS were wrist, knee, MCP; 34% later developed CTD (28% RA, 2% lupus 3% other CTD). Progression predicted by +RF (HR 2.9), PIP (HR 2.4), Wrist (HR 2.5) & female (HR 2.2)
Dr. John Cush RheumNow
5 years 11 months ago
Safety of nintedinib (NIN)in PSS-ILD - 576 PSS pts given NIN 150 mg bid or PBO x52wks. Dose lowered to 100 mg bid for AE. Diarrhea seen in 76% of NIN and 32% in PBO (d/c in 6.9% & 0.3%). Dose reduction in 48% & 12%. RCT discontinuation in 16% & 8.7% https://t.co/v5NxwlHu37
A new short‐term follow‐up study has shown no significant difference in outcomes and quality measures in patients with RA who were managed by telemedicine (compared to usual in-person care).
QD Clinic - Episodic Arthritis
Palindromic Rheumatism - Differential Dx and Rx
Dr. John Cush RheumNow
5 years 11 months ago
PI facts: did you know that JAK inhibitors(UPA, Bari, Tofa) have a warning against use w/ severe liver problems. They have not been studied in pts w/ Hepatitis B or C. UPA Bari & toga can be used in mild liver dz; Tofa only at 5 mg/d w/ moderate liver dz https://t.co/lnXrf12tjA
Dr. John Cush RheumNow
5 years 11 months ago
Listent to QD Clinics - A Podcast Weekly Compilation - Lessons from the clinic. Dr. Jack Cush discusses triage Rheumatology; Im Not Stupid; & Swollen but Not Painful
iTunes https://t.co/FHJv01Sb3a
SoundCloud https://t.co/fceBeXGu09
Dr. John Cush RheumNow
5 years 11 months ago
RheumNow Podcast is up! Back Talk: Taking Calls ^ Questions from Listeners - watch it here>https://t.co/KuTtu5JawO or listen to the Podcast on iTunes> https://t.co/FHJv01AAbC
OR SoundCloud> https://t.co/ICukowi11u
Yesterday the Food and Drug Administration's (FDA) "Vaccines and Related Biological Products Advisory Committee" convened a panel of experts to assess the development of vaccines for COVID-19 infection.
